Intraperitoneal Chemotherapy with Mitomycin C or Cisplatin
Intraperitoneal dissemination is a frequently observed form of recurrence after gastric cancer surgery. It has been reported that positivity of a cytological examination of free cancer cells in the peritoneal cavity after curative resection of gastric cancer is as high as 16%, and all the patients with positive cytological results died within 5 years after the surgery .The most important merit of intraperitoneal (i.p.) chemotherapy lies in that a much higher drug concentration in the peritoneal cavity can be achieved compared with that achieved with intravenous (i.v.) chemotherapy [2, 3, 4, 5].
KeywordsGastric Cancer Methylene Blue Clin Oncol Gastric Cancer Patient Advanced Gastric Cancer
Unable to display preview. Download preview PDF.
- 10.Hiratsuka M, Ogawa A, Ohigashi H, Kameyama M, Sasaki Y, Ishikawa O, Kabuto T, Fukuda I, Furukawa H, Imaoka S, Koyama H, Iwanaga T (1988) Dosage and its safety on intraperitoneal high dose mitomycin C administration as postoperative adjuvant therapy for gastric cancer. J Jpn Soc Cancer Ther 23:1574–1579Google Scholar
- 16.Hiratsuka M, Furukawa H, Iwanaga T, Nakamori S, Masutani S, Ohigashi H, Kameyama M, Sasaki Y, Kabuto T, Ishikawa O, Koyama H, Imaoka S (1993) Pharmacokinetics following intraperitoneal sequential administration of cisplatin and fluorouracil for gastric cancer. Jpn J Cancer Chemother 20:1627–1630Google Scholar
- 17.Japanese Research Society for Gastric Cancer (1995) Japanese classification of gastric carcinoma, 1st English edition. Kanehara, TokyoGoogle Scholar
- 19.Hiratsuka M, Furukawa H, Iwanaga T, Tamura S, Yasuda T, Nakamori S, Ohigashi H, Kameyama M, Sasaki Y, Kabuto T, Ishikawa O, Imaoka S (1998) Peritoneal lavage cytology and intraperitoneal chemotherapy. In: Yonemura Y (ed) Peritoneal dissemination: molecular mechanisms and the latest therapy. Maeda Shoten, Kanazawa, Japan, pp 201–214Google Scholar
- 21.Rosen HR, Jatzko G, Repse S, Potrc S, Neudorfer H, Sandbichler P, Zacherl J, Rabl H, Holzberger P, Lisborg P, Czeijka M (1998) Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian working group for surgical oncology. J Clin Oncol 16:2733–2738PubMedGoogle Scholar
- 22.Hiratsuka M, Furukawa H, Yasuda T, Murata K, Nakano H, Ohigashi H, Kameyama M, Sasaki Y, Kabuto T, Ishikawa O, Imaoka S (1998) Report of case who survived more than five years after repeated intraperitoneal chemotherapy with cisplatin and 5-fluorouracil for treatment of macroscopically negative but microscopically positive peritoneal dissemination of gastric cancer. Jpn J Cancer Chemother 25:1445–1448Google Scholar
- 23.Atiq OT, Kelsen DP, Shiu MH, Saltz L, Tong W, Niedzwiecki D, Trochanowski B, Lin S, Toomasi F, Brennan M (1993) Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. J Clin Oncol 11:425–433PubMedGoogle Scholar
- 25.Sugarbaker PH, Graves T, DeBruinjn EA, Cunliffe WJ, Mullins RE, Hull WE, Oliff L, Schlag P (1990) Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. Cancer Res 50:5790–5794PubMedGoogle Scholar
- 26.Kelsen D, Karpeh M, Schwartz G, Gerdes H, Lightdale C, Botet J, Lauers G, Klimstra D, Huang Y, Saltz L, Quan V, Brennan M (1996) Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J Clin Oncol 14:1818–1828PubMedGoogle Scholar